Aldevron Breakthrough Blog: Plasmid DNA

Apply for the Nanoplasmidᵀᴹ AAV Construct Giveaway

Overcoming challenges, increasing yields

In efforts to bring the next-generation of plasmid technology to the cell and gene therapy space, Aldevron is offering a giveaway to customers developing AAV based therapies. Nanoplasmid benefits in the context of AAV include improved ITR stabilization from its proprietary host strain while increasing plasmid yields compared to conventional plasmid vectors. 

Read More

Eliminate Protein and Antibiotic Markers

Advantages of the Nanoplasmid RNA-OUT Marker System

For decades, the same plasmid technology has been used in vaccination, cell and gene therapy, and as a raw material in viral vector and RNA production, but that technology often isn’t a good fit for the processes where it’s being used. Now, with the growing availability of Nanoplasmid™ vectors, that is changing.

Read More

A Focus on Analytics, for RNA and Beyond

Driving innovation of industry tools

Analytical innovation is often overlooked in discussions of biotechnology product development and manufacturing processes. For example, in the DNA area, most “state of the art” analytical methods in use were developed in the 1980s, or even earlier. Industrywide, there is a need to continuously innovate in the analytical space due to the tremendous advances in enabling technologies.

Read More

Webinar on Demand: Advanced Plasmid Technology – Improving Safety and Performance

Nanoplasmid™ Vectors: The Power of Small

In cell and gene therapies, delivery is a critical factor. Regardless of your modality, optimizing payload, impact, and duration are common challenges. Countless programs, globally, are working on the delivery mechanism. However, many have overlooked a key component in improving therapeutic or manufacturing performance: the plasmid.

Read More

A Complete Suite of rAAV Constructs

New ITR Cloning and Reporter Constructs Now Available
By Jeff Briganti, Senior Director, Global Strategic Marketing

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category.

For recombinant adeno-associated virus (rAAV) viral vector production, we now offer several off-the-shelf ITR cloning backbones and GFP reporter constructs to complement our standardized set of OTS helper and packaging plasmids. This product set is available license and royalty free for research through commercial rAAV applications.

Utilizing this standardized portfolio can provide significant time and cost reduction, expediting time to market and de-risking specialized, transformative therapeutic development. By partnering with a contract development and manufacturing organization (CDMO) offering a complete suite of plasmids for viral vector production, researchers can streamline their upfront development while minimizing supply chain disruption throughout their program’s lifecycle.

For full information about our new product offering or to request a sample, visit our pALD-ITR Products page.

Read More

The Benefits of Streamlining and Standardizing Plasmid DNA for Cell and Gene Therapies

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category. 
Read More

Applying Experience - Partnering with Pioneers to Deliver Plasmid for Discovery Through Commercial Application: On Demand Video

Aldevron recently hosted a webinar through FIERCE Biotech titled: Applying Experience - Partnering with Pioneers to Deliver Plasmid for Discovery Through Commercial Application.

Listen below to hear featured presentations from Cindy Biffert, VP of GMP Nucleic Acids Business Unit at Aldevron, Barry Byrne, M.D, P.h.D, Associate Chair of Pediatrics and Professor at UFL, Director of Powell Gene Therapy Center, and Earl and Christy Powell University Chair in Genetics, and Christine Sheaffer, Manufacturing Operations Lead at Spark Therapeutics. 

Read More